MedTrace Logo

Study of SRF617 in Patients With Advanced Solid Tumors

NCT04336098 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2024-06-04

No results posted yet for this study

Summary

A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

SRF617

SRF617 prevents CD39 mediated conversion of adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to adenosine monophosphate (AMP) and phosphate, leading to an increase in extracellular ATP and a reduction in adenosine levels within the tumor microenvironment (TME). There is an important role for extracellular ATP and adenosine in cancer maintenance and progression, and maintaining high levels of ATP (and low levels of adenosine) in the TME may have anticancer therapeutic activity.

DRUG

Gemcitabine

Gemcitabine as an intravenous (IV) infusion

DRUG

Albumin-Bound Paclitaxel

Albumin-bound paclitaxel as an IV infusion

DRUG

Pembrolizumab

Pembrolizumab as an IV infusion .

Sponsors & Collaborators

  • Surface Oncology

    collaborator INDUSTRY

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Coherus Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Alison O'Neill, MD · Surface Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-16
Primary Completion
2023-08-25
Completion
2023-08-25
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04336098 on ClinicalTrials.gov